Overview
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Eligibility
Inclusion Criteria:
- Histologically confirmed advanced breast cancer
- Hormone receptor-positive and human epidermal growth factor receptor 2-negative
- ECOG 0-1
Exclusion Criteria:
- Pregnant or breastfeeding
- History of immunodeficiency